Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
LM-102
i
Other names:
LM-102
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
LaNova Medicines Limited
Drug class:
CLDN18.2 inhibitor
Related drugs:
‹
zolbetuximab-clzb (11)
ZL-1211 (4)
TJ-CD4B (4)
AZD5863 (3)
AB011 (2)
ASP2138 (2)
TST001 (2)
MIL93 (1)
Q-1802 (1)
ASKB589 (0)
BNT141 (0)
DR30303 (0)
FL-301 (0)
IBI-389 (0)
IBI360 (0)
LB4330 (0)
PM1032 (0)
PM3023 (0)
PT886 (0)
QLS31905 (0)
SG1906 (0)
TAC101-Claudin18.2 (0)
AMG 910 (0)
zolbetuximab-clzb (11)
ZL-1211 (4)
TJ-CD4B (4)
AZD5863 (3)
AB011 (2)
ASP2138 (2)
TST001 (2)
MIL93 (1)
Q-1802 (1)
ASKB589 (0)
BNT141 (0)
DR30303 (0)
FL-301 (0)
IBI-389 (0)
IBI360 (0)
LB4330 (0)
PM1032 (0)
PM3023 (0)
PT886 (0)
QLS31905 (0)
SG1906 (0)
TAC101-Claudin18.2 (0)
AMG 910 (0)
›
Associations
News
Trials
Filter by
Latest
over1year
Study of LM-102 in Patients With Advance Solid Tumors (clinicaltrials.gov)
P1/2, N=11, Terminated, LaNova Medicines Development Co., Ltd. | N=265 --> 11 | Trial completion date: Jun 2025 --> Feb 2023 | Recruiting --> Terminated | Trial primary completion date: Mar 2025 --> Feb 2023; company adjusted strategy
over 1 year ago
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
CLDN18 (Claudin 18)
|
CLDN18.2 positive
|
LM-102
2years
Study of LM-102 in Subjects in Advanced Tumors (clinicaltrials.gov)
P1, N=9, Terminated, LaNova Medicines Limited | N=30 --> 9 | Trial completion date: Mar 2023 --> May 2022 | Recruiting --> Terminated | Trial primary completion date: Mar 2023 --> May 2022; Business strategy changed
2 years ago
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
|
CLDN18 (Claudin 18)
|
CLDN18.2 positive
|
LM-102
3years
Study of LM-102 in Patients With Advance Solid Tumors (clinicaltrials.gov)
P1/2, N=265, Recruiting, LaNova Medicines Development Co., Ltd. | Not yet recruiting --> Recruiting
3 years ago
Clinical • Enrollment open • Combination therapy
|
CLDN18 (Claudin 18)
|
CLDN18.2 positive
|
LM-102
3years
Study of LM-102 in Patients With Advance Solid Tumors (clinicaltrials.gov)
P1/2, N=265, Not yet recruiting, LaNova Medicines Development Co., Ltd.
3 years ago
Clinical • New P1/2 trial • Combination therapy
|
CLDN18 (Claudin 18)
|
CLDN18.2 positive
|
LM-102
over3years
Study of LM-102 in Subjects in Advanced Tumors (clinicaltrials.gov)
P1, N=30, Recruiting, LaNova Medicines Limited | Initiation date: Dec 2020 --> Jun 2021
over 3 years ago
Clinical • Trial initiation date
|
CLDN18 (Claudin 18)
|
LM-102
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login